Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I Think

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 28, 2022 11:46am

147 Views

Post# 34371566

RE:I Think

Sorry that was directed to anyone on this site or any site that continues to pose as someone in the know with devious answers , meanwhile their answer means nothing. If folks come to these boards because they are too lazy to do their own research, shame on them. But don't presume that you know what I am questioning here these guys are so heavy into this stock that they would say anything......and besides , is this BB so busy with other posts, not opinions, not even close. Without this dialogue there would be no one here. Things are not what they would like you to think, there is nothing going on with this stock at the moment, nothing. CLAS with/or without R107 have others nipping at their heels.... now.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale